ArticlePharmacoEconomics2024

Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.

William L Herring et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.